A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)‐based to sirolimus‐based immunosuppression in liver transplant recipients with impaired renal function
Christopher J.E. Watson, Alexander E.S. Gimson, Graeme J. Alexander, Michael E.D. Allison, Paul Gibbs, Jane C. Smith, Christopher R. Palmer, J. Andrew Bradley – 28 November 2007 – Renal impairment is common in patients after liver transplantation and is attributable in large part to the use of calcineurin inhibitor (CNI)‐based immunosuppression. We sought to determine whether conversion to sirolimus‐based immunosuppression was associated with improved renal function.